Nevada Senate Bill 128 from the 2025 83rd Legislature is a health care reform measure that addresses two significant areas of patient autonomy and medical freedom. The first major provision prescribes requirements governing the denial of requests for prior authorization, establishing rules that limit insurance companies' ability to arbitrarily block treatment recommendations from physicians. The second provision encourages licensed physicians, physician assistants, advanced practice registered nurses, and osteopathic physicians to discuss with patients information relating to stem cell treatment, storage, and donation, expanding patients' access to information about innovative treatment options. The bill passed the Nevada Senate with 15 votes in favor and 6 opposed on April 22, 2025, and then passed the Nevada Assembly with 23 votes in favor and 16 opposed on May 31, 2025, demonstrating bipartisan support for health freedom measures. Though the bill was ultimately vetoed by the Governor on June 10, 2025, its progression through the legislature reflects growing recognition that patients deserve greater control over their medical decisions and access to emerging treatments. The legislation directly challenges regulatory and insurance barriers that have historically prevented patients from learning about or pursuing innovative stem cell therapies and other advanced treatment options.

Why It Matters to MAHA

Nevada SB128 embodies core MAHA principles by reducing regulatory barriers that limit patient choice and expanding access to information about innovative treatments like stem cell therapy. The prior authorization reform component directly addresses one of the most frustrating obstacles to patient autonomy: insurance company gatekeeping that overrides physician recommendations and delays or denies medically appropriate care. By requiring transparent, accountable standards for denying prior authorization requests, this bill shifts power back to the patient-physician relationship and away from bureaucratic insurance intermediaries who lack the medical expertise and personal knowledge of individual patients. The stem cell treatment provisions represent a critical victory for health freedom by encouraging physicians to inform patients about cutting-edge regenerative medicine options that many patients are currently unaware of or are actively discouraged from pursuing. This aligns perfectly with MAHA's commitment to transparency in healthcare and ensuring patients have access to the full range of treatment options available, including innovative therapies that may not yet be fully approved through traditional regulatory channels. The bill recognizes that patients have the right to make informed decisions about their own bodies and medical futures, including storage and donation of stem cells for future therapeutic use.